This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO)

Tipranks - Tipranks - Tue Jun 9, 8:44AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO).

Introducing TipRanks MCP for Agents

Cullinan Management (CGEM)

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Cullinan Management, with a price target of $28.00. The company’s shares closed last Monday at $13.95.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 34.8% and a 62.9% success rate. CFA covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Dianthus Therapeutics, and Viridian Therapeutics. ;'>

Currently, the analyst consensus on Cullinan Management is a Strong Buy with an average price target of $30.17, representing a 123.3% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $38.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Pfizer (PFE)

Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Pfizer on June 6 and set a price target of $27.00. The company’s shares closed last Monday at $25.99.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 5.5% and a 51.1% success rate. Gould covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. ;'>

Pfizer has an analyst consensus of Hold, with a price target consensus of $29.10, which is an 11.8% upside from current levels. In a report issued on May 26, Citi also maintained a Hold rating on the stock with a $27.00 price target.

Novo Nordisk (NVO)

BMO Capital analyst Evan Seigerman reiterated a Hold rating on Novo Nordisk yesterday and set a price target of $45.00. The company’s shares closed last Monday at $42.23.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 6.6% and a 51.4% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

Currently, the analyst consensus on Novo Nordisk is a Hold with an average price target of $45.25, representing a 5.3% upside. In a report issued on June 3, Goldman Sachs also maintained a Hold rating on the stock with a $47.00 price target.

Read More on CGEM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).